
    
      This is a phase II, multicenter, randomized, placebo-controlled, parallel group study of
      EpiCeptâ„¢ NP-1 Topical Cream (amitriptyline 4%/ketamine 2%) in approximately 200 patients with
      chronic pain in the lower extremities due to diabetic peripheral neuropathy (DPN).
    
  